Your browser doesn't support javascript.
Discovery and development of safe-in-man broad-spectrum antiviral agents.
Andersen, Petter I; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjørås, Magnar; Telling, Kaidi; Lutsar, Irja; Dumpis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.
  • Andersen PI; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
  • Ianevski A; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
  • Lysvand H; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
  • Vitkauskiene A; Department of Laboratory Medicine, Lithuanian University of Health Science, 44307 Kaunas, Lithuania.
  • Oksenych V; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
  • Bjørås M; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
  • Telling K; Institute of Technology, University of Tartu, 50090 Tartu, Estonia.
  • Lutsar I; Institute of Medical Microbiology, University of Tartu, Tartu 50411, Estonia.
  • Dumpis U; Latvian Biomedical Research and Study Centre, Riga 1067, Latvia.
  • Irie Y; Institute of Technology, University of Tartu, 50090 Tartu, Estonia.
  • Tenson T; Institute of Technology, University of Tartu, 50090 Tartu, Estonia.
  • Kantele A; Helsinki University Hospital (HUS) and University of Helsinki, Helsinki 00290, Finland.
  • Kainov DE; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway; Institute of Technology, University of Tartu, 50090 Tartu, Estonia; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, 00014 Helsinki, Finland. Electroni
Int J Infect Dis ; 93: 268-276, 2020 Apr.
Article in English | MEDLINE | ID: covidwho-1172
ABSTRACT
Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-specific vaccines and antiviral drugs are the most powerful tools to combat viral diseases. However, broad-spectrum antiviral agents (BSAAs, i.e. compounds targeting viruses belonging to two or more viral families) could provide additional protection of the general population from emerging and re-emerging viral diseases, reinforcing the arsenal of available antiviral options. Here, we review discovery and development of BSAAs and summarize the information on 120 safe-in-man agents in a freely accessible database (https//drugvirus.info/). Future and ongoing pre-clinical and clinical studies will increase the number of BSAAs, expand the spectrum of their indications, and identify drug combinations for treatment of emerging and re-emerging viral infections as well as co-infections.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Discovery / Drug Development Type of study: Prognostic study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2020 Document Type: Article Affiliation country: J.ijid.2020.02.018

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Discovery / Drug Development Type of study: Prognostic study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2020 Document Type: Article Affiliation country: J.ijid.2020.02.018